38 results about "Streptococcus infection" patented technology

The invention relates to a tilapia immune potentiator and a preparation method thereof, and belongs to the technical field of an aquatic compound feed additive. The preparation method is characterized by comprising the following steps: fully mixing curcumin, glutamine, betaine and a carrier; and crushing the components into dry powder. The tilapia immune potentiator has the advantages of stable raw material source, simple preparation process, wide material selection range and low cost; starting from an immune mechanism of fish, Chinese herbal medicines and a western medicine-glutamine dipeptide are supplemented in the immune potentiator; and by means of combination of the traditional Chinese medicines and the western medicine, immunity of the fish is improved. By utilizing the tilapia immune potentiator, the immunity and oxidation resistance of the fish are improved, the capability of tilapia on resisting pathogenic streptococcus infection is strengthened, and growth of the tilapia is promoted.

The (Streptococcus suis Serotype 2 (SS2) virulence gene PCR amplification kit includes a SS2DNA contrast template, a PCR amplification detecting reagent, an agarose gel electrophoresis reagent and a DNA gradient standard. The PCR amplification detecting process includes the measurement of 7 important SS2 genes, diagnosing Streptococcus infection and SS2 infection based on whether to amplify specific Streptococcus gene, specific SS2 gene and 5 relevant important SS2 virulence genes, and predicting the virulence, invasiveness trend and disease prognosis fast and early. The present invention is favorable to the clinical diagnosis of borderline case and early warning, and is hopeful to be applied in emergency detection of human SS2 infection, etc.

The invention discloses a care solution for cleaning a nasal cavity and a preparation method of the care solution. The care solution is prepared from 5,000 parts of traditional Chinese medicine distillate, 0.1-2 parts of preservatives, 1-100 parts of glyceryl polymethacrylate, 20-100 parts of tween 80, 30-80 parts of sodium chloride, 20-60 parts of a pH conditioning agent and 4658-4928.9 parts of purified water. The osmotic pressure of the care solution is 280-310mosm/Kg, and the pH value is 5.5-7.0. The preparation method of the care solution mainly comprises the following steps: by taking one or combination of houttuynia cordata, mint, honeysuckle and radix angelicae as raw materials, carrying out steam distillation to obtain the traditional Chinese medicine distillate; matching with auxiliary materials, and then filtering and carrying out split charging, so as to obtain the care solution. The solution disclosed by the invention has a strong inhibiting effect on nasal common microbe streptococcus infection, staphylococcus, bacillus influenza, influenza viruses and rhinoviruses, and can achieve the target of preventing rhinitis infection and recurrence.

The invention provides application of S. pneumoniae protein to resisting infection of S. pneumoniae. The endopeptidase O (PepO) of S. pneumoniae is a subcutaneous immunologic adjuvant, and the prepared S. pneumoniae protein vaccines have the good protection effects on resisting infection of S. pneumoniae through mixing and fusing expression of the subcutaneous immunologic adjuvant and 673rd to 863rd amino acid peptide fragment of zinc metal protease B (ZmpB).

The invention provides a group B streptococcus nucleic acid assay kit based on a PCR (polymerase chain reaction) fluorescent probe method. The group B streptococcus nucleic acid assay kit comprises nucleic acid releasing agents and PCR reaction fluid, wherein the nucleic acid releasing agents include 0.05-0.5mM/L surfactin, 100-300mM/L potassium chloride, 0.05-3% sodium dodecyl sulfate and 0.01-1% ethyl alcohol, the PCR reaction fluid comprises a forward primer, a reverse primer and a probe, the forward primer and the reverse primer are used for target polynucleotide amplification, and the probe is used for target polynucleotide assay. The group B streptococcus nucleic acid assay kit has the advantages that a nucleic acid release method is adopted, a pathogen coat protein structure is rapidly destroyed by strong protein denaturants, group B streptococcus-DNA (deoxyribonucleic acid) in unknown samples such as genital secretions and rectum secretions of perinatal pregnant women can be assayed rapidly, and assay sensitivity can be up to 500 copies/ml, so that reliable experimental bases are provided for group B streptococcus infection diagnosis, and the problems of poor assay specificity and low sensitivity of the prior art can be solved.

The invention discloses a method for detecting group B streptococcus infection, which is characterized in that a detection reagent prepared from hippuric acid or hippurate analogue as a chromogenic substrate and a buffer solution is adopted, and hippuricase in group B streptococcus can be used for specifically recognizing glycine and benzoic acid in the chromogenic substrate and hydrolyzing amido bonds for linking glycine and benzoic acid to change the color of the chromogenic substrate, so that whether group B streptococcus is infected or not in a detected sample is judged. The invention also discloses a kit for detecting group B streptococcus infection. The detection method disclosed by the invention is simple, professional training required for the bacterial streaking technology is not needed, identification results can be obtained only by simple sample adding and short-time incubation, the detection time is far shorter than the time required for culture by a culture medium, and visual identification results are intuitive and accurate. The kit disclosed by the invention is simple in structure, convenient in operation and good in performance. Statistics show that by adopting the kit for detection, the positive predictive value is more than 85%, and the negative predictive value is more than 97%.

The invention discloses a fusion protein vaccine capable of inhibiting Streptococcus and/or preventing Streptococcus infection. With fusion protein obtained through linkage of sortase A and a cholera toxin B subunit through connecting peptide, the Th17 cell activation level is remarkably increased, the effects of preventing pathogenic bacteria from settling and quickly removing the pathogenic bacteria can be realized, and the fusion protein has protecting effects on Group A Streptococcus of different serotypes and has the superiority of high efficiency, broad spectrum and low cost. With the fusion protein, the use amount of immunogen is reduced, the production technology is simplified, and the production cost is reduced. Meanwhile, the vaccine adopts the way of mucosal immunity, has the characteristics of being free of tissue damage, free of local side effects and convenient to use, and is easy to popularize and use.

Polypeptides from Streptococcus pneumoniae are described. In some aspects the polypeptides include pili polypeptides from a second pili island (pilus II island (INVl 04B)) identified in Streptococcus pneumoniae isolate INVl 04. In other aspects the polypeptides include pili polypeptides and non-pilus polypeptides from Streptococcus pneumoniae strains 23F, INV200, and OXC141 that are absent from Streptococcus pneumoniae isolate INV104. The polypeptides, including fragments and variants thereof, may be used in immunogenic compositions for prophylactic or therapeutic immunization against Streptococcus pneumoniae. The polypeptides are also disclosed to be used in compositions useful for the production of antibodies and immunostimulants. Also presented are methods of inhibiting Streptococcus pneumoniae, methods of treating Streptococcus pneumoniae infection, methods of identifying inhibitors of Streptococcus pneumoniae and methods for diagnosing/detecting Streptococcus pneumoniae infection.

The invention belongs to the technical field of screening and application of probiotics, and particularly relates to a Lactobacillus paracasei strain for preventing streptococcus infection of infants and an application of the Lactobacillus paracasei strain. The lactobacillus paracasei has a very strong antibacterial effect on beta-hemolytic streptococcus and is preserved in the China Center for Type Culture Collection on May 24, 2021, and the preservation number of the lactobacillus paracasei is CCTCC (China Center for Type Culture Collection) NO: M2021591. The strain can effectively prevent streptococcus infection, especially streptococcus infection of infants, can significantly reduce the level of inflammatory factors in the body, alleviate the degree of shedding of intestinal mucosa layers, keep the mesenteric structure complete, and alleviate inflammatory cell infiltration and splenomegaly, and has outstanding effects. The lactobacillus paracasei can be used for preparing food, health care products, medicines or skin care products with the function of preventing streptococcus infection, and the application prospect is wide.

The invention belongs to the technical field of prevention and treatment of animal infectious diseases, and particularly relates to application of a PBD-2 (Porcine Beta-Defensin 2) peptide fragment topreparation of a medicine composition for preventing and treating streptococcus suis infection. The PBD-2 peptide fragment has no cytotoxicity in vitro and has an obvious inhibition effect on streptococcus suis growth. Through PBD-2 treatment, the mortality rate, the inflammatory cytokine level, the tissue bacterial load quantity and the pathology damage degree of mice infected with streptococcussuis can be obviously reduced. The invention provides basic candidate medicine for pharmaceutical application of the PBD-2 peptide fragment to preparation of medicine for preventing and treatment thestreptococcus suis infection.

The invention discloses a method for detecting group B streptococcus infections and belongs to methods for determining characteristics of in-vivo blood. According to the method, a kit contains reagents for detection, such as a negative control serum, a positive control serum, a concentrated phosphate buffer, an adsorbent, isosulfocyanic acid fluorescein-labeled sheep anti-human-IgM globulin and a mounting medium and a biological thin sheet, and reaction areas of the biological thin sheet are coated with group B streptococci. A determination method comprises the steps of adding an IgG antibody removed diluted serum into the reaction areas, carrying out incubation, rinsing and spin-drying, then, adding the isosulfocyanic acid fluorescein-labeled sheep anti-human-IgM globulin, forming isosulfocyanic acid fluorescein-labeled sheep anti-human-IgM globulin fluorescent complexes around thalli, and generating green-yellow fluorescence. According to the method disclosed by the invention, indexes such as sensitivity and specificity are all higher than that of the existing methods.

Isolated proteins and immunogenic fragments thereof, for use in the treatment and prevention of a Group A Streptococcus infection are provided. In particular, the invention provides pharmaceutical compositions and methods of prophylactic and/or therapeutic treatment of a Group A Streptococcus infection.

The invention belongs to the technical field of screening and application of probiotics, and particularly relates to a novel lactobacillus paracasei strain and an application of the lactobacillus paracasei strain. The provided lactobacillus paracasei is separated from fresh excrement of healthy infants, and is preserved in the China Center for Type Culture Collection on May 24, 2021, and the preservation number of the lactobacillus paracasei is CCTCC (China Center for Type Culture Collection) NO: M2021590. The strain has a very strong antibacterial effect on beta-hemolytic streptococcus, can improve the immunity of a host, relieve inflammatory response and effectively prevent and treat infection caused by streptococcus, and is particularly suitable for preventing streptococcus infection of infants.

The invention discloses a genital tract PCR system capable of reducing PCR competition of three fluorescent channels, and relates to molecular biology. The genital tract PCR system comprises six sets of primers and probes containing six genital tract pathogens, dNTPs, a glycerol-free hot start-up enzyme, MgCl2, a freeze-drying protective additive and the like. The six genital tract pathogens are chlamydia trachomatis, neisseria gonorrhoeae, ureaplasma urealyticum, mycoplasma hominis, mycoplasma genitalium and group B streptococcus. The probe of the chlamydia trachomatis and the mycoplasma hominis adopts a double-quenching probe capable of reducing a fluorescent background, so that the PCR amplification efficiency of the vulnerable party of the two gene competition parties is improved. The PCR system can be used for detecting infertility caused by venereal disease infection genital tract pathogens and group B streptococcus infection during pregnancy. The PCR system is convenient to use and simple to operate, and can meet the sensitivity required by competition of various fluorescence channels.